We previously showed that RT alone can enhance the anti-tumor immune response leading to improved tumor control in a CD8+ T cell dependent manner.21 Here, to interrogate the impact of combination RT and anti-PD-L1 on local and abscopal tumor control as well as CD8+ T cell subsets, B16F10 cells expressing the lymphocytic choriomeningitis (LCMV) glycoprotein (B16F10GP), which allow for the identification of tumor-specific T cells21, were sequentially implanted on bilateral flanks of wt C57BL/6 mice (Figure 1A). The gene discussed is CD8A; the disease is neoplasm.